Van Cutsem, E, Eefsen, R L, Ochsenreither, S, Zvirbule, Z, Ivanauskas, A, Arnold, D, Baltruskeviciene, E, Pfeiffer, P, Yachnin, J, Garcia Carbonero, R, Greil, R, Jungels, C, Poulsen, L, Awada, A, Garcia Ribas, I, Losic, N & Collignon, J 2022, ' Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). ', Journal of Clinical Oncology, vol. 40, no. Suppl. 16, pp. 4141 . < https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4141 > Web of Science